Details About Generic Salt ::  Reteplas

Main Medicine Class:: Tissue plasminogen activator.   

(REH-tuh-place)
Retavase
Class: Tissue plasminogen activator.

 

Drugs Class ::

 Action Aids in dissolution of blood clots.

Indications for Drugs ::

 Indications Management of acute MI, to reduce incidence of congestive heart failure and mortality associated with an acute MI.

Drug Dose ::

 Route/Dosage

ADULTS: IV 10 + 10 U double-bolus injection, each bolus given over 2 mins. The second bolus given 30 mins after initiation of the first.

Contraindication ::

 Contraindications Active internal bleeding; history of cerebrovascular accident; recent intracranial or intraspinal surgery or trauma; intracranial neoplasm, arteriovenous malformation or aneurysm; bleeding diathesis or severe uncontrolled hypertension because thrombolytic therapy increases the risk of bleeding.

Drug Precautions ::

 Precautions

Pregnancy: Category C. Lactation: Undetermined. Children: Safety and efficacy not established. Bleeding: Most frequent and serious side effect. Arrhythmias: Antiarrhythmic therapy should be available because coronary reperfusion may result in arrhythmias.

PATIENT CARE CONSIDERATIONS


Drug Side Effects ::

 Adverse Reactions

HEMA: Bleeding, both superficial (eg, venous cutdowns, arterial punctures, sites of surgical intervention), and internal (eg, GI tract, GU tract, pericardial, retroperitoneal sites).

Drug Mode of Action ::  

 Action Aids in dissolution of blood clots.

Drug Interactions ::

 Interactions

Abciximab, aspirin, dipyridamole, heparin, vitamin K antagonists: May increase the risk of bleeding. INCOMPATIBILITIES: Heparin: Do not add other medications to the same IV.

Drug Assesment ::

 Assessment/Interventions

  • Obtain patient history, including drug history and any known allergies. Note cerebrovascular disease, hypertension or recent internal bleeding.
  • Obtain drug history, noting use of aspirin, dipyridamole or heparin because these drugs may increase the risk of bleeding.
  • Ensure that coagulation studies have been performed before administration. These tests provide baseline values against which to monitor patient’s response to therapy.
  • Take pulse and BP before administration and monitor frequently during infusion.
  • Observe for internal or external bleeding before and during infusion.
  • Carefully monitor potential bleeding sites (eg, catheter insertion sites, arterial puncture sites) because fibrin will be lysed during therapy, resulting in new or increased bleeding.
  • Avoid IM injections and nonessential handling of patient during treatment.
  • Minimize number of arterial and venous punctures.
  • If arterial punctures are necessary, use site accessible to manual compression. Use manual pressure for at least 30 min, apply pressure and check site frequently for evidence of bleeding.
  • If serious bleeding occurs, stop infusion and any concomitant heparin and notify physician.
  • Observe for indications of hypersensitivity (eg, urticaria, fever). Nausea, vomiting, hypotension and fever are frequent sequelae of MI and may or may not be attributable to therapy.
  • If anaphylactic reaction occurs, stop infusion, notify physician and initiate appropriate therapy.
OVERDOSAGE: SIGNS & SYMPTOMS
  Bleeding.

Drug Storage/Management ::

 Administration/Storage

  • Available only as powder for reconstitution for IV administration.
  • Administer by IV infusion only.
  • Reconstitute immediately before use; only with accompanying Sterile Water for Injection (without preservatives) following reconstitution instructions. Do not shake.
  • Allow to stand after reconstitution until all large bubbles are dissipated.
  • Solution may be stored up to 4 hrs at room temperature (36°–86°F).
  • Do not administer if solution is discolored or if particles are present.
  • Store at room temperature. Protect from light.

Drug Notes ::

 Patient/Family Education

  • Explain drug action and need for frequent monitoring, including blood tests and vital signs.
  • Instruct patient to report any new bleeding sites or increased bleeding, dizziness, headache, numbness or tingling.
  • Tell patient to report urticaria or fever.
  • Instruct patient to avoid getting out of bed without assistance during treatment.

Disclaimer ::

The Information available on this site is for only Informational Purpose , before any use of this information please consult your Doctor .Price of the drugs indicated above may not match to real price due to many possible reasons may , including local taxes etc.. These are only approximate indicative prices of the drug.

We would like to keep you updated with special notifications.